New Drug Development

 

New Drug Approval

1 Marzulene-S Combination Granules Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
(launched in Japan at 1968, China at 1990, India at 2000)
2 Azuloxa Granules 2.5% Gastric ulcer therapeutic agent
(launched in Japan at 2001, launched in Korea 2004)
3 Marzulene Combination Tablets 1.0ES Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
(Dosage form addition: launched in Japan at 2003)
4 Marzulene Combination Tablets 0.5ES Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
(Dosage form addition: launched in Japan at 2008)
5 Marzulene Combination Tablets 0.375ES Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
(Dosage form addition: launched in Japan at 2009)
6 Azuloxa Tablets 15mg Gastric ulcer therapeutic agent
(launched in Japan at 2011)
7 Suglat Tablets 25mg/50mg
Ipragliflozin(ASP1941)
Type2 Diabetes therapeutic agent/SGLT2 Inhibitor for Treatment
(launched in Japan at 2014, launched in Korea at 2015, Joint development with Astellas Pharma Inc.)
八重枝垂桜

 

R&D Pipeline(2018.1.31)

 

1 MK-0431J (Ipraglifulozin / Sitagliptin) ①Development stage:Japan / Approval application
②Target:Type 2 diabetes ③Joint development:Astellas, MSD
2 Ipragliflozin ①Development stage:Japan / Approval application
②Target:Type 1 diabetes ③Joint development:Astellas
3 ASP2215 (giliteritinib)
(“sakigake” fast-track drug)
①Development stage:the United States, Europe, Japan, Asia / Phase Ⅲ
②Target:Acute myeloid leukemia ③Development:Astellas
4 S-556971(KT6-971) ①Development stage:Japan / Phase Ⅱ, Europe / Phase I
②Target:Dyslipidemia ③Development:Kotobuki
5 KT7-533:α-C-Galactosyl Ceramide (Phase I in preparation:Derivation ending)

 

ビデオ会議

 

中圧液体クロマトグラフィー

medium pressure liquid chromatography